CAJ | 학술논문

目的：对比百奥蚓激酶和前列地尔注射液治疗糖尿病肾病的临床疗效，为临床治疗方案的制定提供参考。方法选取我院收治的糖尿病肾病患者100例，随机分为观察组和对照组各50例。观察组在常规治疗的基础上加用百奥蚓激酶胶囊口服治疗，对照组在常规治疗的基础上加用前列地尔注射液静脉滴注治疗。治疗4周后对比两组患者治疗前后的尿素氮（BUN）、肌酐（SCr）和24 h尿蛋白定量检测结果，同时观察两组患者治疗过程中的不良反应发生情况。结果经过治疗后，观察组BUN水平为（7.92±5.37）mmol/L，SCr水平为（87.46±37.29）μmol/L，24 h尿蛋白定量水平为（191.39±69.27）mg，全血粘度低切水平为（5.28±1.96）cp，纤维蛋白原水平为（3.02±0.27）g/L。对照组BUN水平为（8.53±4.38）mmol/L，SCr水平为（89.19±35.31）μmol/L，24 h 尿蛋白定量水平为（181.36±64.16）mg，全血粘度低切水平为（5.36±1.73）cp，纤维蛋白原水平为（3.06±0.35）g/L。两组患者治疗后的24 h尿蛋白定量、全血黏度低切、纤维蛋白原检查结果均显著低于治疗前（P＜0.05），观察组治疗后BUN水平显著低于治疗前（P＜0.05），两组患者治疗后的BUN、SCr、24 h尿蛋白定量、全血黏度低切、纤维限蛋白原检查结果的对比，差异均没有统计学意义（P＞0.05）；两组患者治疗过程中均未发生严重的不良反应。结论百奥蚓激酶可有效减少糖尿病肾病患者的蛋白尿，提高糖尿病肾病的临床疗效，其服用方便，值得临床推广应用。
목적：대비백오인격매화전렬지이주사액치료당뇨병신병적림상료효，위림상치료방안적제정제공삼고。방법선취아원수치적당뇨병신병환자100례，수궤분위관찰조화대조조각50례。관찰조재상규치료적기출상가용백오인격매효낭구복치료，대조조재상규치료적기출상가용전렬지이주사액정맥적주치료。치료4주후대비량조환자치료전후적뇨소담（BUN）、기항（SCr）화24 h뇨단백정량검측결과，동시관찰량조환자치료과정중적불량반응발생정황。결과경과치료후，관찰조BUN수평위（7.92±5.37）mmol/L，SCr수평위（87.46±37.29）μmol/L，24 h뇨단백정량수평위（191.39±69.27）mg，전혈점도저절수평위（5.28±1.96）cp，섬유단백원수평위（3.02±0.27）g/L。대조조BUN수평위（8.53±4.38）mmol/L，SCr수평위（89.19±35.31）μmol/L，24 h 뇨단백정량수평위（181.36±64.16）mg，전혈점도저절수평위（5.36±1.73）cp，섬유단백원수평위（3.06±0.35）g/L。량조환자치료후적24 h뇨단백정량、전혈점도저절、섬유단백원검사결과균현저저우치료전（P＜0.05），관찰조치료후BUN수평현저저우치료전（P＜0.05），량조환자치료후적BUN、SCr、24 h뇨단백정량、전혈점도저절、섬유한단백원검사결과적대비，차이균몰유통계학의의（P＞0.05）；량조환자치료과정중균미발생엄중적불량반응。결론백오인격매가유효감소당뇨병신병환자적단백뇨，제고당뇨병신병적림상료효，기복용방편，치득림상추엄응용。
Objective To compare the clinical efficacy of Lumbrokinase and Alprostadil Injection in treatment of diabetic nephropathy, and to provide the reference for clinical treatment. Methods 100 patients with diabetic nephropathy were selected in our hospital. They were randomly divided into observation group and control group with 50 cases in each. In the observation group based on routine treatment combined with Lumbrokinase capsules for treatment, the control group on the basis of conventional therapy plus Alprostadil Injection intravenous infusion therapy. Urea nitrogen before and after 4 weeks of treatment, compared two groups of patients (BUN), creatinine (SCr) and detection of 24 hour urinary protein quantitative results, and observe the adverse re-actions of the two groups of patients in the process of occurrence. Results After treatment,the observation group BUN level was (7.92±5.37) mmol/L,SCr level was (87.46±37.29) μ mol/L,24 hour urinary protein quantitative level was (191.39±69.27) Mg, the whole blood viscosity at low shear level was (5.28±1.96) CP, fibrinogen level was (3.02±0.27) g/L. control group BUN level (8.53± 4.38) mmol/L, SCrlevel was (89.19± 35.31) μ mol/L, 24 hour urinary protein quantitative level was (181.36±64.16) Mg, the whole blood viscosity at low shear levelwas (5.36±1.73) CP, fibrinogen level was (3.06±0.35) g/L. Two groups of patients after the 24 hour urinary protein quantity, blood viscosity of low shear, fibrinogen test results were significantly lower than that before treatment ( P<0.05), the observation group after treatment BUN wassignificantly lower than that before treatment ( P< 0.05), the twogroups after treatment BUN, SCr, 24hours urine proteinthe comparison of the whole blood viscosity, low shear, the fiber limiting proteinexami-nation results, the differences were not statistically significant (P>0.05);the twogroups of patients during treatment were not seriou-sadverse reactions. Conclusion Lumbrokinase capsules can effectively reduce the proteinuria in diabetic nephropathy patients, im-prove the curative effect of diabetic nephropathy, which is convenient to take, it is worthy of clinical application.